Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco.
Dina DaaboulMarwan OsmanIssmat I KassemIman YassineDelphine GirlichAlexis ProustChemsi MounirKhalid ZeroualiJosette RaymondThierry NaasSaoussen OueslatiPublished in: The Journal of antimicrobial chemotherapy (2024)
The isolation of XDR P. aeruginosa isolates expressing several carbapenemases in a neonatal intensive care unit is of great concern due to the reduced treatment options, relying only on colistin, but not recommended in neonates, and apramycin, not yet approved for human therapy. Concerns were further elevated due to the resistance to cefiderocol and ATM/AVI, two novel and last-resort antibiotics recommended to treat infections caused by Gram-negative bacteria, particularly XDR P. aeruginosa in adults.
Keyphrases
- pseudomonas aeruginosa
- klebsiella pneumoniae
- drug resistant
- acinetobacter baumannii
- multidrug resistant
- gram negative
- endothelial cells
- cystic fibrosis
- escherichia coli
- preterm infants
- biofilm formation
- intensive care unit
- dna damage
- acute kidney injury
- induced pluripotent stem cells
- low birth weight
- dna repair
- septic shock
- pluripotent stem cells
- dna damage response
- staphylococcus aureus
- stem cells
- drug administration
- cell therapy
- wild type